181 results
Page 9 of 10
6-K
EX-99.1
jhmug7s
26 Jul 18
Bioblast Pharma Ltd. Corporate and Management Update
4:35pm
6-K
EX-99.1
gt6chrx
18 Apr 17
Current report (foreign)
12:00am
6-K
EX-99.1
gk4y77sv
24 Oct 16
Bioblast Announces Results of Trehalose Clinical Study
12:00am
424B5
i1bwm
18 Mar 16
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
ga5d9a04
27 Oct 15
Current report (foreign)
12:00am
6-K
EX-99.1
foohuss4igow8dp h4
9 Oct 15
Appoints Former Aptalis and Novartis Executive, Theresa M. Stevens, as Chief Corporate Development Officer
12:00am
20-F
vy8 s8o4l8h112120zsp
31 Mar 15
Annual report (foreign)
12:00am
6-K
EX-99.1
3ea830tlnm4d
2 Feb 15
Bio Blast Announces Key Leadership Changes
12:00am
6-K
EX-99.1
rbc5 yh4dn5vw
8 Jan 15
Current report (foreign)
12:00am
6-K
EX-99.1
r1rpurrz9g92niv
17 Dec 14
BioBlast Receives Notice of Patent Issuance from USPTO for Its Novel Fusion Protein-Based Platform for the Treatment of Friedrich’s Ataxia
12:00am
6-K
EX-99.1
gkof vt6p
21 Nov 14
Bio Blast Pharma Reports Third Quarter Financial Results
12:00am
6-K
EX-99.1
sn1nuc
19 Nov 14
Bio Blast Pharma Receives Orphan Drug Designation
12:00am
6-K
EX-99.1
cak1j 7gvgweuo
22 Sep 14
Bio Blast Pharma Announces Initiation of its Canadian OPMD Clinical Study Center at McGill University, Montreal
12:00am
6-K
EX-99.1
xsxznjpuvfzsvpbgg
17 Sep 14
BioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results with Cabaletta, Interim Safety Results from Phase 2/3HOPEMD Study in OPMD
12:00am
6-K
EX-99.1
gojhou9 xf4ap
29 Aug 14
BioBlast Pharma Reports Second Quarter Financial Results
12:00am
424B4
w1l1s9ea3rp
31 Jul 14
Prospectus supplement with pricing info
12:00am
F-1/A
EX-3.2
6enjfvhzc
8 Jul 14
Registration statement (foreign) (amended)
12:00am